Pfizer (PFE)

These stocks offer a good mix of dividends, growth, and long-term stability.

The pharma giant's yield of around 7.1% is more than six times the S&P 500 average.

Cathie Wood's biotech ETF has largely moved on from the vaccine maker.

Drug pricing matters, but pipelines matter even more.

Wainua missed its Phase 3 endpoint, hitting Ionis Pharmaceuticals hard while AstraZeneca absorbed the blow easily, boosting rivals BridgeBio, Pfizer and Alnylam Pharmaceuticals.

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ...

These high-yield stocks have long track records of dividend consistency and growth.

There are good reasons to invest in Lilly and to hold off.

So far, Pfizer has been an also-ran in the GLP-1 race, but that could change if its long-acting weight-loss medication takes off.

FDA approves Pfizer and Astellas' PADCEV plus Keytruda for muscle-invasive bladder cancer, backed by Phase 3 survival data.

Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built the...

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have be...

AstraZeneca stock crashed Thursday after its Ionis-partnered treatment for a rare heart disease failed in Phase 3 testing.

They may not remain cheap for too much longer.

A 7% dividend yield will grab your attention, but be sure to read the fine print.

Hospira brand bacteriostatic water is a sterile, non-pyrogenic preparation of water for injection that contains 0.9

Pfizer was downgraded to Hold as analysts cited delayed pipeline catalysts, management changes and reduced near-term re-rating potential.

One stands above the others.

Could this be the secret to Pfizer's rebound strategy?

Analysts have given Alnylam Pharmaceuticals an average price target of $436.

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...

These stocks offer high yields, are big names in their respective sectors, and have strong fundamentals.